61.85
price down icon0.74%   -0.46
after-market Dopo l'orario di chiusura: 61.80 -0.05 -0.08%
loading
Precedente Chiudi:
$62.31
Aprire:
$62.32
Volume 24 ore:
22,622
Relative Volume:
0.51
Capitalizzazione di mercato:
$1.97B
Reddito:
-
Utile/perdita netta:
$-32.61M
Rapporto P/E:
-52.67
EPS:
-1.1742
Flusso di cassa netto:
-
1 W Prestazione:
+1.41%
1M Prestazione:
+3.64%
6M Prestazione:
+4.09%
1 anno Prestazione:
+28.53%
Intervallo 1D:
Value
$61.01
$62.48
Intervallo di 1 settimana:
Value
$59.12
$62.64
Portata 52W:
Value
$43.70
$86.53

Belite Bio Inc Adr Stock (BLTE) Company Profile

Name
Nome
Belite Bio Inc Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
25
Name
Cinguettio
Name
Prossima data di guadagno
2025-03-17
Name
Ultimi documenti SEC
Name
BLTE's Discussions on Twitter

Confronta BLTE con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
BLTE
Belite Bio Inc Adr
61.85 1.94B 0 -32.61M 0 -1.1742
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
472.27 120.73B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
564.64 61.80B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.00 42.46B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.74 35.22B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
296.46 31.99B 3.81B -644.79M -669.77M -6.24

Belite Bio Inc Adr Stock (BLTE) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2023-12-14 Iniziato Maxim Group Buy
2023-07-28 Iniziato Cantor Fitzgerald Overweight
2023-07-26 Iniziato SVB Securities Outperform
2022-08-01 Iniziato H.C. Wainwright Buy
2022-07-01 Iniziato The Benchmark Company Buy

Belite Bio Inc Adr Borsa (BLTE) Ultime notizie

pulisher
Jul 23, 2025

Belite Bio Executives Share Latest Retinal Disease Breakthroughs at BTIG Biotech Conference - Stock Titan

Jul 23, 2025
pulisher
Jul 22, 2025

New Strong Sell Stocks For July 22nd - Barchart.com

Jul 22, 2025
pulisher
Jul 22, 2025

New Strong Sell Stocks for July 22nd - Zacks Investment Research

Jul 22, 2025
pulisher
Jul 19, 2025

What analysts say about Belite Bio Inc Depositary Receipt stockConsistent wealth multiplication - jammulinksnews.com

Jul 19, 2025
pulisher
Jul 16, 2025

Belite Bio concludes enrollment for phase 3 GA trial on oral tinlarebant - Eyes On Eyecare

Jul 16, 2025
pulisher
Jul 16, 2025

Stargardt Disease Pipeline 2025: FDA Approvals and Clinical Trials Landscape with MOA and ROA Highlights by DelveInsight | Nanoscope Therapeutics, Belite Bio, Biophytis, reVision Therapeutics, Inc - The Globe and Mail

Jul 16, 2025
pulisher
Jul 15, 2025

Analysts Offer Insights on Healthcare Companies: Neumora Therapeutics, Inc. (NMRA), Solid Biosciences (SLDB) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

Jul 15, 2025
pulisher
Jul 11, 2025

Q2 EPS Estimates for Belite Bio Decreased by Leerink Partnrs - Defense World

Jul 11, 2025
pulisher
Jul 10, 2025

Ouster Announces Date for Second Quarter 2025 Earnings Call - The Globe and Mail

Jul 10, 2025
pulisher
Jul 09, 2025

Belite Bio, Inc.’s Tinlarebant: Promising Treatment for Stargardt Disease with Significant Market Potential - TipRanks

Jul 09, 2025
pulisher
Jul 08, 2025

Phase 3 PHOENIX trial for oral GA treatment completes enrollment - Modern Retina

Jul 08, 2025
pulisher
Jul 03, 2025

Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress - Investing.com India

Jul 03, 2025
pulisher
Jul 02, 2025

Belite Bio Completes Enrollment for Phase 3 PHOENIX Trial on Tinlarebant - TipRanks

Jul 02, 2025
pulisher
Jul 02, 2025

Major Breakthrough: First-Ever Oral Treatment for Geographic Atrophy Reaches Full Phase 3 Enrollment - Stock Titan

Jul 02, 2025
pulisher
Jun 12, 2025

Analysts Issue Forecasts for Belite Bio FY2026 Earnings - Defense World

Jun 12, 2025
pulisher
Jun 11, 2025

Reviewing Belite Bio (NASDAQ:BLTE) & ZyVersa Therapeutics (NASDAQ:ZVSA) - Defense World

Jun 11, 2025
pulisher
Jun 07, 2025

Bank of America Corp DE Acquires 4,891 Shares of Belite Bio, Inc (NASDAQ:BLTE) - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

Cohen & Company Inc. (NYSEAMERICAN:COHN) Stock Price Crosses Above Two Hundred Day Moving Average – Here’s What Happened - Defense World

Jun 07, 2025
pulisher
Jun 05, 2025

Belite Bio, Inc (NASDAQ:BLTE) Shares Sold by Citadel Advisors LLC - Defense World

Jun 05, 2025
pulisher
May 31, 2025

BNP Paribas Financial Markets Acquires New Shares in Belite Bio, Inc (NASDAQ:BLTE) - Defense World

May 31, 2025
pulisher
May 24, 2025

What is HC Wainwright’s Forecast for Belite Bio Q1 Earnings? - Defense World

May 24, 2025
pulisher
May 23, 2025

What is HC Wainwright's Estimate for Belite Bio Q2 Earnings? - MarketBeat

May 23, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod By Investing.com - Investing.com Nigeria

May 22, 2025
pulisher
May 22, 2025

Belite Bio stock holds $80 target on FDA breakthrough nod - Investing.com

May 22, 2025
pulisher
May 22, 2025

Belite Bio’s Promising Outlook: FDA Breakthrough Designation and Upcoming Milestones Boost Buy Rating - TipRanks

May 22, 2025
pulisher
May 21, 2025

Yi Chen Recommends Buy Rating for Belite Bio Due to Breakthrough Therapy Designation and Promising Trial Progress - TipRanks

May 21, 2025
pulisher
May 21, 2025

Why Belite Bio’s Stock is Soaring High - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio’s Tinlarebant Receives FDA Breakthrough Therapy Designation for Stargardt Disease - TipRanks

May 21, 2025
pulisher
May 21, 2025

Belite Bio Says FDA Grants Breakthrough Therapy Tag to Stargardt Disease Drug - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting Of Breakthrough Therapy Designation For Tinlarebant For The Treatment Of Stargardt Disease - marketscreener.com

May 21, 2025
pulisher
May 21, 2025

Belite Bio Receives FDA Breakthrough Therapy Designation for Tinlarebant in Treating Stargardt Disease - Nasdaq

May 21, 2025
pulisher
May 21, 2025

Belite Bio Announces FDA Granting of Breakthrough Therapy - GlobeNewswire

May 21, 2025
pulisher
May 20, 2025

Analysts Offer Insights on Healthcare Companies: Centessa Pharmaceuticals (CNTA), Arcellx Inc (ACLX) and Belite Bio, Inc. ADR (BLTE) - The Globe and Mail

May 20, 2025
pulisher
May 19, 2025

Q2 Earnings Estimate for Belite Bio Issued By HC Wainwright - Defense World

May 19, 2025
pulisher
May 17, 2025

Belite Bio (NASDAQ:BLTE) Earns “Overweight” Rating from Cantor Fitzgerald - Defense World

May 17, 2025
pulisher
May 17, 2025

HC Wainwright Reaffirms Buy Rating for Belite Bio (NASDAQ:BLTE) - Defense World

May 17, 2025
pulisher
May 16, 2025

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing - GlobeNewswire

May 16, 2025
pulisher
May 16, 2025

Benchmark maintains Buy on Belite Bio stock, $80 price target unchanged - Investing.com Nigeria

May 16, 2025
pulisher
May 15, 2025

Belite Bio’s Earnings Call Highlights Clinical Progress and Financial Strength - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Transcript : Belite Bio, Inc Presents at Deutsche Bank ADR Virtual Investor Conference, May-15-2025 12 - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio at Deutsche Bank Conference: Promising Drug Trials - Investing.com

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald - Investing.com Australia

May 15, 2025
pulisher
May 15, 2025

Belite Bio stock retains Overweight rating at Cantor Fitzgerald By Investing.com - Investing.com India

May 15, 2025
pulisher
May 15, 2025

Promising Clinical Trials and Strategic Developments Justify Buy Rating for Belite Bio - TipRanks

May 15, 2025
pulisher
May 15, 2025

Belite Bio Advances Clinical Trials Amid Financial Challenges - TipRanks

May 15, 2025
pulisher
May 14, 2025

Earnings call transcript: Belite Bio’s Q1 2025 sees narrower EPS loss - Investing.com Nigeria

May 14, 2025
pulisher
May 14, 2025

Earnings Flash (BLTE) Belite Bio Q1 Loss $0.45 Vs. FactSet Est. $0.35 Loss - marketscreener.com

May 14, 2025
pulisher
May 14, 2025

Belite Bio Q1 2025 Earnings Call Transcript - MarketBeat

May 14, 2025
pulisher
May 14, 2025

Belite Bio Advances Tinlarebant Trials with Positive Interim Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Belite Bio, Inc Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com

May 14, 2025

Belite Bio Inc Adr Azioni (BLTE) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.63
price up icon 3.32%
$36.59
price up icon 1.61%
$103.52
price up icon 0.08%
$27.57
price down icon 1.57%
$114.57
price down icon 0.03%
biotechnology ONC
$296.46
price up icon 0.55%
Capitalizzazione:     |  Volume (24 ore):